Mode
Text Size
Log in / Sign up
N/A Completed N=963

Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011)

Hepatitis C, Chronic
Source: ClinicalTrials.gov NCT01098097 ↗
Enrolled (actual)
963
Serious AEs
1.9%
Results posted
Nov 2012
Primary outcomePrimary: Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs) — 33.6; 1.9 percentage of participants

Summary

To study retreatment in patients who failed prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin in a real-life setting in an observational/noninterventional study.

Outcome Measures

OutcomeResultp-value
PRIMARY
Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs)
33.6; 1.9 —
PRIMARY
Incidence of Thrombocytopenia
3.8 —
PRIMARY
Incidence of Treatment Discontinuations Due to Adverse Events
2.6; 0.1 —
PRIMARY
Incidence of Particular Adverse Events Resulting in Treatment Discontinuation
0.6; 0.2; 0.2; 0.1; 0.0; 0.0 —
PRIMARY
Incidence of Dose Modifications Due to Adverse Events
9.7; 0.1; 0.3 —
SECONDARY
Proportion of Participants Who Achieve Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)
42.4 —

Eligibility Criteria

Inclusion Criteria

  • Chronic hepatitis C of any genotype;
  • Prior treatment with interferon alpha (pegylated or non-pegylated) with or without ribavirin did not result in a sustained virological response;
  • Inclusion criteria listed on the approved label in each country;
  • Willingness of the patient to participate and sign the Informed Consent Form.

Exclusion Criteria

  • Patient exclusion from this observational/non-interventional study will be determined by the treating physician and will be based on the local label in each country.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01098097). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search